×
IBio Price/Book Ratio 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
IBio price/book ratio from 2010 to 2024. Price/book ratio can be defined as
View More
IBio Price/Book Ratio 2010-2024 | IBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
IBio price/book ratio from 2010 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$159.1B
Vertex Pharmaceuticals (VRTX)
$124.6B
Bristol Myers Squibb (BMY)
$118.6B
Gilead Sciences (GILD)
$114.8B
CSL (CSLLY)
$88.8B
Regeneron Pharmaceuticals (REGN)
$86B
GSK (GSK)
$71.3B
Argenex SE (ARGX)
$35.6B
Alnylam Pharmaceuticals (ALNY)
$33.3B
BioNTech SE (BNTX)
$24.8B
Biogen (BIIB)
$24B
Illumina (ILMN)
$22.6B
BeiGene (BGNE)
$18.8B
Moderna (MRNA)
$15.3B
Incyte (INCY)
$15B
Genmab (GMAB)
$14B
Insmed (INSM)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.5B
Vaxcyte (PCVX)
$11.6B
Bio-Techne Corp (TECH)
$11.5B
Sarepta Therapeutics (SRPT)
$10.4B
Exelixis (EXEL)
$10B
Revolution Medicines (RVMD)
$9.7B
QIAGEN (QGEN)
$9.6B
Exact Sciences (EXAS)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.5B